SSDV Annual Congress 2025
< back to event website
Converia – Conference Management Software

Detailed contribution information

Back to list

Contribution title Nemolizumab long-term safety and efficacy up to 56 weeks in ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis
Authors
  1. Diamant Thaçi University of Lübeck, Germany
  2. Carle Paul Department of Dermatology, Medical University of Toulouse
  3. Kim A. Papp Alliance Clinical Trials and Probity Medical ResearchWaterloo, Ontario, Canada. University of Toronto, Toronto, Ontario, Canada
  4. Marjolein S. De Bruin-Weller Department of Dermatology and Allergology, Utrecht University/UMC
  5. Matthias Augustin Universitätsklinikum Hamburg-Eppendorf
  6. Ketty Peris Institute of Dermatology, Catholic University of the Sacred Heart, Italy; Fondazione Policlinico Universitario A. Gemelli, IRCCS
  7. Sebastien Barbarot Department of Dermatology, University Hospital, Nantes, France
  8. Andrew Alexis Weill Cornell Medicine, Department of Dermatology, New York
  9. Soo Yeon Cheong Galderma
  10. Liliana Ulianov Galderma
  11. Christophe Piketty Galderma
  12. Marlene Gassner Galderma SA Presenter
Form of presentation Poster
Topic
  • 1.1 Inflammatory and immune-mediated dermatoses